Scandinavian Medical Solutions: Renewed focus on capital allocation
Oversigt
- Scandinavian Medical Solutions experienced challenging market conditions in 2024/25, with earnings and margins at the lower end of expectations, but revenue slightly exceeded guidance.
- The company saw significant improvement in order intake and earnings in the second half of 2024/25, suggesting a conservative outlook for 2025/26 earnings.
- The focus is shifting from market position defense to enhancing profitability and capital allocation, which are expected to drive the short-term investment case.
- HC Andersen Capital, which receives payment from Scandinavian Medical Solutions, provides further details in a presentation of the FY 2024/25 results.
This content is generated by AI. You can give feedback on it in the Inderes forum.
We have updated our investment case one-pager on Scandinavian Medical Solutions following the 2024/25 report and the guidance for 2025/26. Besides an overview of financials and updated valuation multiples, the investment case one-pager introduces Scandinavian Medical Solutions and highlights key investment reasons and risks.
2024/25 was characterized by challenging market conditions, with earnings and margins coming in at the lower end of the range, while revenue slightly exceeded guidance. It was thus a year in which the company defended its market position and invested in future growth – but also a year of two halves, with order intake and earnings increasing significantly in the second half.
Looking at the signals in the later part of 2024/25, a slight increase in earnings as guidance indicates in 2025/26 looks a little conservative. Furthermore, focus now seems to shift from defending their market position to profitability and capital allocation. Delivering on the latter will be the main drivers of the short-term investment case.
For further details on the 2024/25 results and the focus points and guidance for next year, you can watch the FY 2024/25 presentation here: https://www.inderes.dk/videos/scandinavian-medical-solutions-praesentation-af-arsrapporten-202425
Disclaimer: HC Andersen Capital receives payment from Scandinavian Medical Solutions for a Digital IR subscription agreement. /Michael Friis 15:00, 25/11-2025.